<bill session="109" type="h" number="5979" updated="2013-07-19T19:57:13-04:00">
  <state datetime="2006-07-28">REFERRED</state>
  <status>
    <introduced datetime="2006-07-28"/>
  </status>
  <introduced datetime="2006-07-28"/>
  <titles>
    <title as="introduced" type="short">Pharmaceutical Benefit Manager Abuse Prevention Act of 2006</title>
    <title as="introduced" type="official">To prevent abusive practices by pharmaceutical benefit managers (PBMs).</title>
  </titles>
  <sponsor id="400040"/>
  <cosponsors/>
  <actions>
    <action state="REFERRED" datetime="2006-07-28">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2006-08-01">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Commerce"/>
    <term name="Conflict of interests"/>
    <term name="Consumer education"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Finance and financial sector"/>
    <term name="Fines (Penalties)"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Informed consent (Medical law)"/>
    <term name="Law"/>
    <term name="Medical ethics"/>
    <term name="Pharmacies"/>
    <term name="Prescription pricing"/>
  </subjects>
  <amendments/>
  <summary>7/28/2006--Introduced.
Pharmaceutical Benefit Manager Abuse Prevention Act of 2006 - Prohibits a pharmaceutical benefit manager from: (1) referring a patient to a pharmacy or other dispenser of pharmaceuticals that is owned or affiliated with the manager; or (2) changing the drug authorization for a patient without the patient's express consent and without informing the patient of the financial consequences. Requires each pharmaceutical benefit manger to publicly disclose any kickbacks or other financial incentives or any relationship with any pharmaceutical manager. Provides for civil penalties for violations.</summary>
</bill>
